Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in PLoS One Retrieve available abstracts of 64 articles: HTML format

Single Articles

January 2025
1. CHAHARLASHKAR Z, Saeedi Honar Y, Abdollahpour-Alitappeh M, Parvizpour S, et al
   Metastatic melanoma: An integrated analysis to identify critical regulators associated with prognosis, pathogenesis and targeted therapies.
   PLoS One. 2025;20:e0312754.
   PubMed     Abstract available
   
   
   
2. HUGDAHL E, Aziz S, Klingen TA, Akslen LA, et al
   Prognostic value of immune biomarkers in melanoma loco-regional metastases.
   PLoS One. 2025;20:e0315284.
   PubMed     Abstract available
   
   
   
3. SHIRALKAR J, Anthony T, McCallum GA, Durand DM, et al
   Correction: Neural recordings can differentiate between spontaneously metastasizing melanomas and melanomas with low metastatic potential.
   PLoS One. 2025;20:e0318831.
   PubMed     Abstract available
   
   
   
4. LEE C, Song B, Kim E, Seo Y, et al
   68Ga-labeled fluorinated benzamide derivatives for positron emission tomography imaging of melanoma.
   PLoS One. 2025;20:e0317489.
   PubMed     Abstract available
   
   
   
5. 
   Expression of Concern: General sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC.
   PLoS One. 2025;20:e0323638.
   PubMed    
   
   
   
6. VON BUBNOFF D, Schmitt C, Goldinger SM, Schadendorf D, et al
   Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab.
   PLoS One. 2025;20:e0321937.
   PubMed     Abstract available
   
   
   
7. PEREZ AL, Zamora M, Bahena M, Aramburo-Williams R, et al
   The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability.
   PLoS One. 2025;20:e0316983.
   PubMed     Abstract available
   
   
   
8. THAPAR P, Rakhra M, Prashar D, Mrsic L, et al
   Skin cancer segmentation and classification by implementing a hybrid FrCN-(U-NeT) technique with machine learning.
   PLoS One. 2025;20:e0322659.
   PubMed     Abstract available
   
   
   
9. LIANG S, Sun T, Jia XS, Cao JM, et al
   Characterization and prediction of non-melanoma skin cancer incidence in China: Joinpoint regression and age-period-cohort model.
   PLoS One. 2025;20:e0319486.
   PubMed     Abstract available
   
   
   
10. KHONGKARAT P, Kitipaspallop W, Puthong S, Pimtong W, et al
    The in cellular and in vivo melanogenesis inhibitory activity of safflospermidines from Helianthus annuus L. bee pollen in B16F10 murine melanoma cells and zebrafish embryos.
    PLoS One. 2025;20:e0325264.
    PubMed     Abstract available
    
    
    
11. JANKOVSKAJA S, Spegel P, Nielsen K, Bjorklund S, et al
    Non-invasive tape sampling of tryptophan and kynurenine in relation to phenylalanine and tyrosine from melanoma and adjacent non-lesional skin: A pilot study.
    PLoS One. 2025;20:e0326457.
    PubMed     Abstract available
    
    
    
12. HERR FL, Antons MJ, Blume LV, Hirner-Eppeneder H, et al
    Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring combined anti-PD-L1/anti-CTLA-4 immunotherapy effects in a murine melanoma model with immunohistochemical validation.
    PLoS One. 2025;20:e0326675.
    PubMed     Abstract available
    
    
    
13. EL MERTAHI A, Ezzine H, Douzi S, Douzi K, et al
    AI-driven skin cancer detection from smartphone images: A hybrid model using ViT, adaptive thresholding, black-hat transformation, and XGBoost.
    PLoS One. 2025;20:e0328402.
    PubMed     Abstract available
    
    
    
14. KOSHAREK AT, Zuleger CL, Glass WS, Eickhoff J, et al
    In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma.
    PLoS One. 2025;20:e0330200.
    PubMed     Abstract available
    
    
    
15. TOLD R, Reumueller A, Kreminger J, Sacu S, et al
    Factors associated with time until metastatic spread in patients with primary uveal melanoma: A retrospective analysis.
    PLoS One. 2025;20:e0328360.
    PubMed     Abstract available
    
    
    
16. WANG H, Zhang Y, Zhang Y, Zhao X, et al
    SpaVGN: A hybrid deep learning framework for high-resolution spatial transcriptomics data reconstruction and spatial domain identification.
    PLoS One. 2025;20:e0329122.
    PubMed     Abstract available
    
    
    
17. CHEN J, He J, Xu X, Sun H, et al
    Exploring the impact of antibody-dependent cellular phagocytosis-related genes on the prognosis of metastatic melanoma.
    PLoS One. 2025;20:e0333916.
    PubMed     Abstract available
    
    
    
18. ZIEGLER-RODRIGUEZ G, De La Cruz-Ku G, Desai A, Delgado LP, et al
    Melanoma in Peru: 1000 patients and 10 years of experience.
    PLoS One. 2025;20:e0323636.
    PubMed     Abstract available
    
    
    
19. 
    Retraction: Overexpressed PKCdelta Downregulates the Expression of PKCalpha in B16F10 Melanoma: Induction of Apoptosis by PKCdelta via Ceramide Generation.
    PLoS One. 2025;20:e0333839.
    PubMed    
    
    
    January 2024
20. PEISEN F, Gerken A, Dahm I, Nikolaou K, et al
    Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.
    PLoS One. 2024;19:e0296253.
    PubMed     Abstract available
    
    
    
21. WIES C, Schneider L, Haggenmuller S, Bucher TC, et al
    Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study.
    PLoS One. 2024;19:e0297146.
    PubMed     Abstract available
    
    
    
22. LIU Y, Wang S, Wei S, Qiu X, et al
    The promotive role of lncRNA MIR205HG in proliferation, invasion, and migration of melanoma cells via the JMJD2C/ALKBH5 axis.
    PLoS One. 2024;19:e0290986.
    PubMed     Abstract available
    
    
    
23. SHIRALKAR J, Anthony T, McCallum GA, Durand DM, et al
    Neural recordings can differentiate between spontaneously metastasizing melanomas and melanomas with low metastatic potential.
    PLoS One. 2024;19:e0297281.
    PubMed     Abstract available
    
    
    
24. VON MONTFORT C, Aplak E, Ebbert L, Wenzel CK, et al
    The role of GAPDH in the selective toxicity of CNP in melanoma cells.
    PLoS One. 2024;19:e0300718.
    PubMed     Abstract available
    
    
    
25. NAEEM A, Anees T
    DVFNet: A deep feature fusion-based model for the multiclassification of skin cancer utilizing dermoscopy images.
    PLoS One. 2024;19:e0297667.
    PubMed     Abstract available
    
    
    
26. JEONG H, Cho YR, Gim J, Cha SK, et al
    GraphMHC: Neoantigen prediction model applying the graph neural network to molecular structure.
    PLoS One. 2024;19:e0291223.
    PubMed     Abstract available
    
    
    
27. 
    Retraction: Dermokine mutations contribute to epithelial-mesenchymal transition and advanced melanoma through ERK/MAPK pathways.
    PLoS One. 2024;19:e0300807.
    PubMed    
    
    
    
28. ALSHAHRANI M, Al-Jabbar M, Senan EM, Ahmed IA, et al
    Analysis of dermoscopy images of multi-class for early detection of skin lesions by hybrid systems based on integrating features of CNN models.
    PLoS One. 2024;19:e0298305.
    PubMed     Abstract available
    
    
    
29. ZHANG L, Zhang L, Zhang C, Shi S, et al
    circTADA2A inhibited SLC38A1 expression and suppresses melanoma progression through the prevention of CNBP trans-activation.
    PLoS One. 2024;19:e0301356.
    PubMed     Abstract available
    
    
    
30. BUJA A, Rugge M, Cozzolino C, Dossi F, et al
    Could the mitotic count improve personalized prognosis in melanoma patients?
    PLoS One. 2024;19:e0302309.
    PubMed     Abstract available
    
    
    
31. COURTENAY LA, Barbero-Garcia I, Martinez-Lastras S, Del Pozo S, et al
    Near-infrared hyperspectral imaging and robust statistics for in vivo non-melanoma skin cancer and actinic keratosis characterisation.
    PLoS One. 2024;19:e0300400.
    PubMed     Abstract available
    
    
    
32. DHEIN ES, Heikkila U, Oevermann A, Blatter S, et al
    Incidence rates of the most common canine tumors based on data from the Swiss Canine Cancer Registry (2008 to 2020).
    PLoS One. 2024;19:e0302231.
    PubMed     Abstract available
    
    
    
33. 
    Retraction: Combination effect of cold atmospheric plasma with green synthesized zero-valent iron nanoparticles in the treatment of melanoma cancer model.
    PLoS One. 2024;19:e0304502.
    PubMed    
    
    
    
34. ZHANG W, Patterson NH, Verbeeck N, Moore JL, et al
    Multimodal MALDI imaging mass spectrometry for improved diagnosis of melanoma.
    PLoS One. 2024;19:e0304709.
    PubMed     Abstract available
    
    
    
35. ABUH SO, Barbora A, Minnes R
    Metastasis diagnosis using attenuated total reflection-Fourier transform infra-red (ATR-FTIR) spectroscopy.
    PLoS One. 2024;19:e0304071.
    PubMed     Abstract available
    
    
    
36. GUO X, Guo Z, Bai P, Guo C, et al
    GPR168 functions as a tumor suppressor in mouse melanoma by restraining Akt signaling pathway.
    PLoS One. 2024;19:e0302061.
    PubMed     Abstract available
    
    
    
37. FRIEDMAN AA, Amzallag A, Pruteanu-Malinici I, Baniya S, et al
    Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
    PLoS One. 2024;19:e0306658.
    PubMed     Abstract available
    
    
    
38. XU C, Yu X, Ding Z, Fang C, et al
    Artificial intelligence-assisted metastasis and prognosis model for patients with nodular melanoma.
    PLoS One. 2024;19:e0305468.
    PubMed     Abstract available
    
    
    
39. WU X, Marmarelis ME, Stephen Hodi F
    Correction: Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma.
    PLoS One. 2024;19:e0309769.
    PubMed     Abstract available
    
    
    
40. WADT KAW, Harbst K, Sjol MMB, Rosengren F, et al
    Characterization of somatic mutations in sporadic uveal melanoma and uveal melanoma in patients with germline BAP1 pathogenic variants.
    PLoS One. 2024;19:e0306386.
    PubMed     Abstract available
    
    
    
41. 
    Expression of Concern: Fisetin Inhibits Human Melanoma Cell Invasion through Promotion of Mesenchymal to Epithelial Transition and by Targeting MAPK and NFkappaB Signaling Pathways.
    PLoS One. 2024;19:e0313108.
    PubMed    
    
    
    
42. CHUNG HJ, Seo N, Han K, Bae H, et al
    Gadoxetic acid-enhanced MRI for the detection of liver metastases from melanoma.
    PLoS One. 2024;19:e0313212.
    PubMed     Abstract available
    
    
    
43. COHEN G, Rapoport B, Chan SW, Ruff P, et al
    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.
    PLoS One. 2024;19:e0309778.
    PubMed     Abstract available
    
    
    
44. 
    Retraction: Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1alpha in Melanoma Cells.
    PLoS One. 2024;19:e0315282.
    PubMed    
    
    
    January 2023
45. ALI A, Madni A, Shah H, Jamshaid T, et al
    Solid lipid-based nanoparticulate system for sustained release and enhanced in-vitro cytotoxic effect of 5-fluorouracil on skin Melanoma and squamous cell carcinoma.
    PLoS One. 2023;18:e0281004.
    PubMed     Abstract available
    
    
    
46. SHAO H, Teramae D, Wells A
    Axl contributes to efficient migration and invasion of melanoma cells.
    PLoS One. 2023;18:e0283749.
    PubMed     Abstract available
    
    
    
47. 
    Retraction: Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p.
    PLoS One. 2023;18:e0282986.
    PubMed    
    
    
    
48. ORLOW I, Sadeghi KD, Edmiston SN, Kenney JM, et al
    InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.
    PLoS One. 2023;18:e0269324.
    PubMed     Abstract available
    
    
    
49. TAJERIAN A, Kazemian M, Tajerian M, Akhavan Malayeri A, et al
    Design and validation of a new machine-learning-based diagnostic tool for the differentiation of dermatoscopic skin cancer images.
    PLoS One. 2023;18:e0284437.
    PubMed     Abstract available
    
    
    
50. PANG JM, Chien PC, Kao MC, Chiu PY, et al
    MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
    PLoS One. 2023;18:e0284744.
    PubMed     Abstract available
    
    
    
51. TABATABAI MA, Bahri N, Matthews-Juarez P, Alcendor D, et al
    The role of histological subtypes in the survival of patients diagnosed with cutaneous or mucosal melanoma in the United States of America.
    PLoS One. 2023;18:e0286538.
    PubMed     Abstract available
    
    
    
52. ZHU H, Zhang P, Shi J, Kou D, et al
    Exosome-delivered circRPS5 inhibits the progression of melanoma via regulating the miR-151a/NPTX1 axis.
    PLoS One. 2023;18:e0287347.
    PubMed     Abstract available
    
    
    
53. DIVINCENZO MJ, Angell CD, Suarez-Kelly LP, Ren C, et al
    Expression of microRNAs and their target genes in melanomas originating from gynecologic sites.
    PLoS One. 2023;18:e0285804.
    PubMed     Abstract available
    
    
    
54. MA W, Wu Z, Maghsoudloo M, Ijaz I, et al
    Dermokine mutations contribute to epithelial-mesenchymal transition and advanced melanoma through ERK/MAPK pathways.
    PLoS One. 2023;18:e0285806.
    PubMed     Abstract available
    
    
    
55. KUHN CK, Meister J, Kreft S, Stiller M, et al
    TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.
    PLoS One. 2023;18:e0281487.
    PubMed     Abstract available
    
    
    
56. CLEVENGER LM, Wrenn JD, Bena J, Sodhi G, et al
    Clustering of uveal melanoma: County wide analysis within Ohio.
    PLoS One. 2023;18:e0290284.
    PubMed     Abstract available
    
    
    
57. HOCK BD, Goddard L, MacPherson SA, Strother M, et al
    Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab.
    PLoS One. 2023;18:e0290793.
    PubMed     Abstract available
    
    
    
58. MAEKAWA N, Konnai S, Hosoya K, Kim S, et al
    Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
    PLoS One. 2023;18:e0291727.
    PubMed     Abstract available
    
    
    
59. CHAN LH, Wang P, Abuhammad S, Lim LRJ, et al
    PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.
    PLoS One. 2023;18:e0292278.
    PubMed     Abstract available
    
    
    
60. 
    Retraction: Enhancing radiosensitivity of melanoma cells through very high dose rate pulses released by a plasma focus device.
    PLoS One. 2023;18:e0294549.
    PubMed    
    
    
    
61. BONERT M, Berzins A, Begum H, Schittenhelm J, et al
    Neuroanatomical location of brain metastases from solid tumours based on pathology: An analysis of 511 patients with a comparison to the provided clinical history.
    PLoS One. 2023;18:e0294154.
    PubMed     Abstract available
    
    
    
62. SOARES PRO, Passos DCS, da Silva FM, da Silva-Giardini APB, et al
    In vitro antiproliferative and apoptotic effects of thiosemicarbazones based on (-)-camphene and R-(+)-limonene in human melanoma cells.
    PLoS One. 2023;18:e0295012.
    PubMed     Abstract available
    
    
    
63. DUNLOP KLA, Keogh LA, Smith AL, Aranda S, et al
    Acceptability and appropriateness of a risk-tailored organised melanoma screening program: Qualitative interviews with key informants.
    PLoS One. 2023;18:e0287591.
    PubMed     Abstract available
    
    
    
64. KHAN S, Khan A
    SkinViT: A transformer based method for Melanoma and Nonmelanoma classification.
    PLoS One. 2023;18:e0295151.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.